Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04931823 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, sponsored by Conjupro Biotherapeutics.

Active
Registry status
Phase 1
Development phase
126
Enrollment target
8
Study locations

NCT04931823 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Conjupro Biotherapeutics. The registered enrollment target is 126 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04931823, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Conjupro Biotherapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
126 participants
Enrollment target
8
Study locations

Study Summary

This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.

Conditions Studied

Solid Tumor

Interventions

  • DRUG CPO-100

Study Locations (8)

California

  • University of California Los Angeles - Los Angeles

Connecticut

  • Yale University School of Medicine - Yale Cancer Center - New Haven

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

North Carolina

  • Carolina BioOncology Institute - Huntersville

Ohio

  • The Cleveland Clinic Foundation - Lyndhurst

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Texas

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas

Virginia

  • Virginia Cancer Specialist - Fairfax

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2021-03-24
Est. Completion 2025-03-01
Phase Phase 1

Sponsor

Conjupro Biotherapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04931823

The ClinicalTrials.gov registry entry for NCT04931823 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower). The listed sponsor is Conjupro Biotherapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which CPO-100 is the first listed.

NCT04931823 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Connecticut, Nevada.

Frequently Asked Questions

What is clinical trial NCT04931823 about?

NCT04931823 is a clinical study titled "Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors". This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult ...

What is the current status of trial NCT04931823?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2021-03-24. Estimated completion is 2025-03-01.

What conditions does trial NCT04931823 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT04931823?

The interventions under investigation include: CPO-100 (DRUG).

Who is sponsoring clinical trial NCT04931823?

This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04931823 being conducted?

This trial has 8 study locations across California, Connecticut, Nevada, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.